WS #14051
Nu Holdings beats with record profit, Goldman Sachs reports strong Q2, and Bristol-Myers gets FDA approval for CELMoD, driving individual stock moves.
Earnings and corporate actions
Nu Holdings beats with record profit, Goldman Sachs reports strong Q2, and Bristol-Myers gets FDA approval for CELMoD, driving individual stock moves.